Seeking Alpha

Acadia Pharmaceuticals (ACAD -10.2%) crashes after disclosing it's discontinuing development for...

Acadia Pharmaceuticals (ACAD -10.2%) crashes after disclosing it's discontinuing development for its AM-831 schizophrenia drug after it failed to "meet pre-determined criteria for further development in Phase I testing." AM-831 was being developed in partnership with Japan's Meiji Seika Pharma.
Comments (1)
  • Deja Vu
    , contributor
    Comments (1291) | Send Message
     
    That is a real tragedy. Mental health drugs do not have a paying clientele clamoring for them.
    13 Jul 2012, 01:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector